WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016090219) BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/090219    International Application No.:    PCT/US2015/063928
Publication Date: 09.06.2016 International Filing Date: 04.12.2015
IPC:
A61K 39/395 (2006.01), A61K 31/33 (2006.01)
Applicants: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. [US/US]; 12902 Magnolia Drive Tampa, Florida 33612 (US).
DANA-FARBER CANCER INSTITUTE [US/US]; 450 Brookline Avenue Boston, Massachusetts 02215 (US)
Inventors: SOTOMAYOR, Eduardo M.; (US).
BRADNER, James; (US).
TAO, Jianguo; (US)
Agent: GILES, P. Brian; (US)
Priority Data:
62/088,327 05.12.2014 US
62/106,885 23.01.2015 US
Title (EN) BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY
(FR) INHIBITEUR DE BROMODOMAINES COMME ADJUVANT EN IMMUNOTHÉRAPIE ANTICANCÉREUSE
Abstract: front page image
(EN)Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a composition comprising a bromodomain inhibitor. Also disclosed is a method for treating cancer in a subject, comprising co-administering to the subject a bromodomain inhibitor and an immunostimulatory agent.
(FR)L'invention montre que l'inhibition des protéines à bromodomaines au sein des cellules présentatrices d'antigènes les oriente vers une réponse plus inflammatoire, induit une diminution de l'expression de la molécule immunosuppressive PDL1, et permet de restaurer la réactivité de cellules T tolérantes. L'invention concerne en conséquence une méthode favorisant l'activation des lymphocytes T lors d'une immunothérapie anticancéreuse chez le patient, consistant en l'administration au patient recevant l'immunothérapie anticancéreuse d'une composition comprenant un inhibiteur des bromodomaines. L'invention concerne également une méthode de traitement anticancéreux chez le patient, comprenant l'administration conjointe au patient d'un inhibiteur de bromodomaines et d'un agent immunostimulant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)